Barinthus Biotherapeutics plc
BRNS
$0.63
-$0.01-1.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 46.01% | -79.52% | -24.77% | -26.85% | -18.78% |
| Total Depreciation and Amortization | -50.80% | -85.04% | 80.06% | 95.87% | -1.10% |
| Total Amortization of Deferred Charges | -25.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -85.33% | 17.89% | 60.44% | 199.26% | 138.84% |
| Change in Net Operating Assets | -77.31% | 90.44% | -250.96% | -110.66% | 239.24% |
| Cash from Operations | -132.42% | 41.06% | -50.83% | -26.05% | 166.76% |
| Capital Expenditure | 100.00% | 100.00% | 83.33% | 98.38% | -281.70% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.72% | 495.61% | 83.33% | 98.38% | -281.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | -100.00% | -99.60% | 667.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -100.00% | -100.00% | -99.60% | 667.89% |
| Foreign Exchange rate Adjustments | 105.69% | -129.72% | 1,597.48% | 726.83% | -754.81% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -160.69% | -3.75% | -4.90% | 2.46% | 134.57% |